GENERAL ORTHOPAEDICS
Chaperonin 10: Short term relief for rheumatoid arthritis patients
Lancet. 2006 Dec 2;368(9551):1964.23 patients with moderate to severe active rheumatoid arthritis were randomized to receive either 5 mg, 7.5 mg, or 10 mg of Chaperonin 10, an anti-inflammatory drug, intravenously twice weekly for 12 weeks. Disease activity score and core disease measures were assessed throughout the course of the study. By the end of the 12 week study, it was determined that improvement in rheumatoid arthritis was found in all three treatment groups with the 10 mg group having consistently better outcome scores than the 5 mg and 7.5 mg groups.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
